Category: Blood

Wayne Memorial Community Health Centers (WMCHC) was recognized by the American Heart Association and American Medical Association for efforts to improve blood pressure control as part of the Target: BP (targetbp.org) initiative, a national evidence-based quality improvement program. WMCHC’s primary care offices earned a Gold level award based on data verifying that high blood pressure is controlled in 70% or more of the adult patients affected across its nine primary care sites. Shown representing WMCHC are, left to right, Michelle Corrigan, RN, clinical care coordinator/risk manager; Jo-Ann Sames, RN, supervisor, Forest City Family Health Center; Jennifer Allison, LPN, practice manager, pediatric services; Christina MacDowell, CNM, DNP, practice manager, Women’s Health Center; Kara Poremba, MSHA, BSN, chief quality officer; Erica Brown, chief development officer; Wynter Newman, chief administrative officer; James Cruse, MD, chief medical officer; Teresa Lacey, RN, CEO and Robert Fortuner, CFO.

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Hundreds of adults with a severe inherited blood disorder could benefit from stem cell transplants to cure their condition under new guidelines by the NHS. Officials said the treatment for thalassaemia – which was previously only available to children – would mean patients no longer require lifelong blood transfusions. Thalassaemia is a rare condition that impacts the production of haemoglobin in the blood. Symptoms include severe anaemia and tiredness, with patients requiring blood transfusions every two to four weeks. The stem cell transplant procedure – known as allogeneic haematopoietic stem cell transplant (Allo-HSCT) – replaces the bone marrow stem cells with ones from a matched sibling donor. It was previously only offered to children due to the risk of complications in adults. Expanding the availability of stem cell transplants to adults living with thalassaemia is another vital step forward to help change the lives of those living with this deeply debilitating condition Prof Sir Stephen Powis New guidance from NHS England’s Clinical Priorities Advisory Group recommended it be made available for eligible patients over 18, with more than 600 people set to benefit. Professor Sir Stephen Powis, NHS England medical director, said: “Expanding the availability of stem cell transplants to adults living with thalassaemia is another vital step forward to help change the lives of those living with this deeply debilitating condition. “Thalassaemia can be an incredibly painful condition with difficult symptoms for patients as well as the impact on their heart, liver and bones, and it’s fantastic that offering this evidence-based curative stem cell treatment can now offer new hope to help significantly improve their quality of life.” There are currently 2,281 people with thalassaemia registered on the National Haemoglobinopathy Registry (NHR) in the UK, including 1,332 over the age of 18. While it is a huge step in the right direction and a monumental win for thalassaemia, we also eagerly await the much-needed approval for gene therapies Romaine Maharaj Romaine Maharaj, UK Thalassaemia Society executive director, hailed the news as a “remarkable milestone”. “While it is a huge step in the right direction and a monumental win for thalassaemia, we also eagerly await the much-needed approval for gene therapies,” she added. “Having both curative options available will grant more patients the chance to live transfusion-independent lives, enhancing both their quality of life and life expectancy.” It comes after a world-first gene therapy for sickle cell disease and beta thalassemia was approved for use The Medicines and Healthcare products Regulatory Agency (MHRA) earlier this month. The treatment, known as Casgevy, is the first to be licensed using gene-editing tool Crispr, for which its inventors were awarded the Nobel prize in 2020. It works by editing the faulty gene in a patient’s bone marrow stem cells so that the body produces functioning haemoglobin.

NEWARK, Del, Nov. 30, 2023 (GLOBE NEWSWIRE) — According to estimates, the blood glucose monitoring devices market will be worth US$14.2 billion by 2024. By 2034, the market is predicted to reach a valuation of US$ 22.2 billion. According to market research, the global aging population and rising diabetes prevalence are responsible for the shift toward blood glucose monitoring equipment. The behavioral shifts, particularly leading a sedentary lifestyle and reduction in physical activities, have had a harmful influence on people’s health, with diabetes and obesity cases rising, with even children exhibiting symptoms. Obesity, age, family history, low socioeconomic position, metabolic syndrome, obesity, as well as bad lifestyle choices, have all been linked to a greater risk of type 2 diabetes mellitus. Obesity is currently understood to be the most significant factor for prediabetes and type 2 diabetes. The buildup of visceral and ectopic fat, which is strongly correlated with hyperinsulinemia and insulin resistance, is now recognized as one of the major risk factors for type 2 diabetes mellitus requiring timely assessment of the condition as well as regular monitoring through blood glucose monitoring devices driving the market growth for these devices. Get a Sample Copy of the Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-18313 The use of steroids by the COVID-19-infected patients resulted in elevated sugar levels and a surge in diabetes cases. Hence, the use of glucose monitoring devices had seen a surge during this period of time. Countries have favorable reimbursement policies for diabetes care products under National Health Insurance. People can access self-monitoring devices at little or no cost in nations where NHI (National Healthcare Insurance) programmers partially or totally cover the cost of these products. A number of technological developments have compelled manufacturers to release devices that can do reliable and quick testing with alternative-site testing and a smaller sample amount, and that are non-invasive or minimally invasive. These advancements will spur a surge in the blood glucose monitoring devices market growth. “Global market expansion for blood glucose monitoring devices is expected to be driven by changes in lifestyle and a decline in physical activity, which will increase obesity and, in turn, insulin resistance giving rise to increased diabetes cases,” opines Sabyasachi Ghosh, Associate Vice President at Future Market Insights (FMI). Key Takeaways: Self-monitoring devices are the leading segment as a product, and hold around 71.4% market value share in 2022, owing to the ease of operation and easy availability of the device. The invasive blood glucose monitoring device segment is set to lead in terms of usage of blood glucose monitoring devices with a market value share of around 72.8% in 2022, due to the wide use of the devices at both hospitals and home. Retail pharmacy holds the highest market share of about 38.2% in the year 2022 in the distribution channel segment due to the easy availability of blood glucose monitoring devices in retail pharmacies. United States is considered the leading region with a value share of 38.8% in 2022, and is expected to show a growth of 7.4% during the forecasted period. Blood Glucose Monitoring Devices Market Size: Data Points Market Insights Market Value 2023 US$ 13.6 Billion Market Value 2024 US$ 14.2 Billion Market Value 2034 US$ 22.2 Billion CAGR 2023 to 2033 4.6 % Competitive landscape Blood glucose monitoring device manufacturers are operating at full capacity to meet the increasing demand for these devices. Market players are manufacturing new and innovative products and are undertaking clinical trials to demonstrate the advantages of these devices in enhancing therapy and supporting behaviour improvements to further increase adoption rates. Key players have initiated promotional activities to introduce the design and engineering of novel devices with enhanced efficacy. Lead With Data-Driven Decisions. Buy Now to Turn Insights into Competitive! https://www.futuremarketinsights.com/checkout/18313 Recent Development In June 2022, Ascensia diabetes care announced that it has received European CE approval for its next-generation Eversense E3 continuous glucose monitoring system. Patients in European markets will have access to this technology from the third quarter of 2022. DexCom in April 2022, announced that it is going to launch a new DexCom ONE, an easy to use real time continuous glucose monitoring system (rt-CGM). DexCom ONE is a wearable device that sends real time glucose level values to a compatible smart device via the DexCom ONE mobile application. Key Players: ARKRAY, Inc. Bayer AG; Medtronic plc F. Hoffmann-La Roche Ltd. Johnson & Johnson Ascensia Diabetes Care Nipro Diagnostics, Inc. Dexcom, Inc. Sanofi Terumo Medical Corporation Novo Nordisk Ypsomed Holdings Prodigy Diabetes Care, LLC GlySens Incorporated ACON Laboratories Nova Biomedical Medtronic Dexcom, Inc. LifeScan IP Holdings, LLC Senseonics Key Segments: By Product: Self-monitoring device Continuous blood glucose monitoring devices By Usage: Non-invasive Invasive By Modality: Standalone Portable By Indication: Type 1 Type 2 Gestational Diabetes By Distribution Channel: Retail Pharmacy Hospital Pharmacy Diagnostic Centres Online Sales By Region: North America Latin America Western Europe Eastern Europe Asia Pacific Excluding Japan (APEJ) Japan Middle East & Africa Author By: Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher. Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation. Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News. Explore Future Market Insights, Inc. Extensive Coverage in Healthcare Domain: Glucose Sensor Market Analysis: In 2022, the global market is expected to be worth US$ 7,588 million. Global sales of glucose sensors are expected to grow at an 8.6% CAGR between 2022 and 2032, totaling around US$ 16,382 million by the end of 2032. Portable Medical Devices Market Trends: The global market is projected to expand at a CAGR of 10.7% during the forecast period. Wearable

‘Blood Sisters’ by Vanessa Lillie. Berkley, 384 pages, $27 Vanessa Lillie expertly balances a compassionate look at Native American culture and a comprehensive examination of the treatment by the government and white settlers, nTFL-L-book-blood-sistersever once allowing these issues to override the gripping plot of “Blood Sisters.” David Grann’s historical book “Killers of the Flower Moon: The Osage Murders and the Birth of the FBI” and the film based on his non-fiction have renewed interest in the plight and violence inflicted on Native Americans. Lillie’s meticulous research and skillful approach in “Blood Sisters” further explores this, joining other Native American mystery writers such as Ramona Emerson (“Shutter”), David Heska Wanbli Weiden (“Winter Counts”) and Marcie R. Rendon (“Sinister Graves”) telling their stories. Lillie, an enrolled citizen of the Cherokee Nation of Oklahoma, focuses “Blood Sisters” on the disappearances of Native American women, a tragedy often ignored by local authorities. The launch of a new series, “Blood Sisters” introduces Cherokee archaeologist Syd Walker, who works for the Rhode Island branch of the Bureau of Indian Affairs (BIA), which has come a long way since its original mission to “exterminate Native people, culture, and ways of life.” Now the agency is revising its image by trying to establish trust with indigenous communities. Syd’s supervisor reassigns her to the Oklahoma branch when her identification card, dating back to her college internship with the BIA, is found inside a skull near her parents’ land. “Blood Sisters,” by Vanessa Lillie (Berkley/Courtesy) Syd hasn’t been to her hometown of Picher in three years. She’s still haunted by dark memories when, 15 years before, two masked men invaded the trailer where she, her sister Emma Lou and best friend Luna Myers were watching TV. Luna and her family were eventually killed. The crime profoundly affected the community, Syd and Emma Lou. Syd went to college where she met her now-wife Mal and found a career while Emma Lou became an opiate addict. Although she has stayed away from Picher, Syd keeps in contact with her parents and sends regular gifts to Emma Lou’s daughter, Gracie. But long-distance contact has shielded Syd from what has been going on with Picher and her family. Unbridled mining has ravaged Picher, leaving the town economically depressed, many houses uninhabitable, some near collapse. Offers from the government to buy some houses has divided the residents. Syd’s family appear to be in league with people Syd considers criminals. Syd has tried to distance herself from Picher, but her boss is right when she says, “The places we’re from live within our DNA.” Syd learns that Emma Lou vanished a few days ago, one of several indigenous women who recently disappeared from the area. Her family insist that Emma Lou has kicked her drug habit, and that her disappearance is out of character. Lillie effectively delivers a moving story melding Native American rights and culture, a broken community and fully realized characters into a concise thriller that contains just enough action to keep the story believable. The intelligent Syd, with her complicated life and dark memories, is a strong character. Set in 2008 with frequent dips into the distant past, “Blood Sisters” works well as a historical mystery and a story about families, Native Americans and prejudice. “Blood Sisters” is an excellent start to what should prove to be a long-running series.

The American Red Cross will be collecting blood donations from 10 a.m. to 4 p.m. on Friday, Dec. 8, at the Dublin Civic Center, 100 Civic Plaza. To schedule a donation, go to TRedCrossBlood.org and use the sponsor code “DublinCommunity” or 94568 zip code, or call 800-733-2767.

Traffic pollution can raise a driver’s blood pressure, study says – CBS Boston Watch CBS News A new study found that pollution from tailpipe exhaust, brake and tire wear, and road dust can raise your blood pressure while you’re sitting in the car. View CBS News In Be the first to know Get browser notifications for breaking news, live events, and exclusive reporting. Not Now Turn On

CHEYENNE, Wyo. — Cheyenne Regional Medical Center is improving patient care in southeast Wyoming as one of the first in the state to offer new, needle-free blood draw technology called the PIVO Pro Needle-free Blood Collection Device. The PIVO Pro Device is a single-use, disposable sterile device that temporarily attaches to a patient’s existing peripheral IV catheter – typically placed in the hand or arm – to collect a blood sample, according to a news release from Cheyenne Regional Medical Center. The device was developed by Becton-Dickinson, one of the largest global medical companies in the world. Traditionally when using a peripheral IV catheter, blood return can be limited due to blockages or obstructions in the catheter. The PIVO Pro Device eliminates these obstacles, allowing clinicians to collect reliable blood samples without creating additional pain and anxiety for the patient. The purpose of the device is to improve the patient experience by minimizing the pain and anxiety of frequent needlesticks. “Blood draws are common in health care, but with more than 60 percent of the adult population having a fear of needles, it can be stressful on the patient,” said Tracy Garcia, CRMC chief nursing officer in the news release. “We are already seeing positive reactions from our patients when they are offered needle-free blood draws.” Since its trial period at CRMC started in November 2023, the PIVO Pro Device has saved 44 patients from additional needlesticks for blood draws. Response from patients has been overwhelmingly positive. “They always have a hard time with my veins, and I get anxiety around needles,” one hospital patient said. “Any hospital that pokes me less will always be the hospital I want to go to.” “This is fascinating. I am a hard stick, and I can’t believe how easy and painless this is,” another patient said about the device. By offering this new standard of care, the medical center is among a growing number of health systems nationwide to join the “One-Stick Hospital Stay” movement to create a better experience for clinicians and patients.

More Videos Giving the gift of life: the Norfolk Sheriff’s Office hosted a blood drive for the community today. Author: 13newsnow.com Published: 6:05 PM EST November 29, 2023 Updated: 6:05 PM EST November 29, 2023

ATLANTA — A community is mourning the loss of a beloved daycare worker, but hoping her death can help make others aware of the dangers of blood clots. Sydney Carter, 27, died from blood clots the day after Thanksgiving. She worked at the Trinity Early Learning Center on Howell Mill Road in Atlanta. Channel 2′s Tyisha Fernandes learned that blood clots are killing more than 100,000 people every year. Carter tried to get to the hospital when she didn’t feel right last week, but it was too late. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] “It’s a major public health crisis,” Leslie Lake with the National Blood Clot Alliance said. Lake told Fernandes she began working with the National Blood Clot Alliance after she had a blood clot that nearly killed her. She says she had been at the hospital for nine hours before doctors performed any tests to check for blood clots. “Almost a million people get a blood clot, and of those who do get one, a lot of them have long-term complications,” Lake explained. “But a lot of it is preventable with more education and awareness which doesn’t exist other than us. This is a public health crisis that really needs to be tackled by the government.” TRENDING STORIES: She also said that Black men and women get more blood clots than anyone else and the rate can be as much as 60% higher than Caucasian people. Typically, blood clots form in your arms or legs and can be deadly if they travel to your lungs. If you have pain, discoloration or your skin is hot for no reason, you should get tested. A state representative here in Georgia is also looking to designate March as Blood Clot Awareness Month. [SIGN UP: WSB-TV Daily Headlines Newsletter] IN OTHER NEWS: Paw-don me, but are you fur real? DeKalb firefighters rescue kitten stuck on I-285 ©2023 Cox Media Group